Skip to main content
Premium Trial:

Request an Annual Quote

FDA Clears SQI Diagnostics' Platform, Test for Celiac Disease

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Canadian life science firm SQI Diagnostics today announced that the US Food and Drug Administration has cleared its SQIDworks platform and IgXPlex celiac qualitative assay.

The 4-plex microarray-based assay tests for anti-tissue transglutaminase IgG and IgA and is the second multiplexed assay cleared by the FDA to run on the SQIDworks platform, after clearance of SQI's IgXplex rheumatoid arthritis assay in late 2009.

The celiac assay previously received regulatory approval in Canada and CE marking in Europe.

Based in Toronto, SQI is developing a 6-plex quantitative celiac panel for the US market, which will include quantitative determinations of IgA and IgG anti-gliadin antibodies, IgA and IgG anti-tissue transglutaminase antibodies, and IgA and IgG anti-deamidated gliadin peptide antibodies, it said.

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.